Non-Hodgkin’s Lymphoma and Chronic Lymphocytic Leukemia | Current Treatment: Physician Insights | US | 2018
Introduction:
Non-Hodgkin’s lymphoma (NHL) is a heterogeneous group of malignancies that can be broadly classified into indolent and aggressive subtypes. The treatment algorithm for NHL continues to evolve as drug labels are expanded and new drugs are added to the armamentarium, such as Bayer HealthCare’s Aliqopa, Kite Pharma/Gilead Sciences’ CAR T-cell therapy Yescarta, and AstraZeneca’s Calquence. This report provides an in-depth analysis of current treatment practices and drivers of therapy selection for key NHL subtypes, including follicular lymphoma, diffuse large B-cell lymphoma, mantle cell lymphoma, and chronic lymphocytic leukemia (CLL).
Questions answered:
- What are the current treatment practices for newly diagnosed and relapsed/refractory NHLsubtypes?
- What is the uptake of recent market entrants in the United States, such as Aliqopa and Calquence?
- What are the key drivers and obstacles determining current prescribing patterns in CLL?
- How do drug-treatment rates vary across NHL/CLL subtypes and practice settings?
PRODUCT DESCRIPTION
Current Treatment: Physician Insights provides physician insights on treatment dynamics, prescribing behavior, and drivers of brand use so you can create specific messaging around these treatment dynamics in order to more effectively increase or defend your market position.
Markets covered: United States
Primary research: Survey of 99 U.S. hematologist-oncologists fielded in April 2018.
Key companies: AbbVie, Acerta Pharma, AstraZeneca, Bayer HealthCare, Celgene, Genmab, Gilead Sciences, Johnson & Johnson, Kite Pharma, Novartis, Roche/Genentech, Takeda, Teva
Key drugs: Aliqopa, Arzerra, Calqueunce, Gazyva, Imbruvica, Revlimid, Rituxan, Velcade, Venclexta, Yescarta, Zydelig
